James Basta was Resigned as Chief Legal Officer, Chief Compliance Officer and Secretary at Kura-Oncology

Date of management change: June 24, 2021 

What Happened?

San Diego, -based Kura-Oncology Resigned James Basta as Chief Legal Officer, Chief Compliance Officer and Secretary


About the Company

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.


About the Person

James Basta is Executive Vice President, General Counsel and Corporate Secretary at Intellia Therapeutics. Previously, James held various senior legal leadership roles in the industry.


Info Source



Other IT executives who recently changed jobs as well: Dehaan-Fullerton Karen, Warren James, Gambill Barbara, Tranchina Elizabeth, Santori Marco, Mayman Todd, Morton Kruse Karen, Nylund Jessica, McClaine Douglas, Condren James, Patheja Angad

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.